$WHWK

Whitehawk Therapeutics presented data at IGCS 2026 showing MUC16 as a stable target in ovarian cancer, supporting its ADC HWK-016 in Phase 1 trials. High MUC16 expression linked to poor survival in HGSOC, the most common subtype. Findings suggest potential for HWK-016 in combination and relapsed settings.

Stifel initiated coverage on Whitehawk Therapeutics (WHWK) with a buy rating and $9.00 price target, citing its Antibody-Drug Conjugates technology. The stock, trading at $3.76, has returned 96% over the past year but is still below InvestingPro’s Fair Value analysis. Stifel highlighted the company’s linker-payload stability and upcoming Phase 1a readouts in 2027.

Whitehawk Therapeutics (Nasdaq: WHWK) presented data at WCLC 2026 showing PTK7 as a stable target for ADC therapy in EGFR wild-type NSCLC, supporting its HWK-007 drug in Phase 1 trials. PTK7 expression remained stable post-treatment, and its expression wasn't linked to survival outcomes, reinforcing its potential as a biomarker. The findings were part of a collaboration with Tempus AI.

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 PRESS RELEASE Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., September 10, 2026 /PRNewswire/ — White

Whitehawk Therapeutics (WHWK) appointed Vijay Iyengar, MD, to its Board of Directors. Iyengar has over 20 years of oncology experience, including senior roles at Incyte and Novartis. The company is a clinical-stage oncology firm developing antibody-drug conjugate (ADC) cancer treatments. Iyengar's expertise is expected to aid Whitehawk's growth and pipeline development.

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments b

Akari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.

Biocytogen (SSE:688796; HKEX:02315) and Whitehawk Therapeutics (Nasdaq:WHWK) announced a global collaboration to develop bispecific antibody-drug conjugates. Biocytogen will supply up to five bispecific antibodies via its RenLite platform; Whitehawk will evaluate them with its ADC linker-payload tech and may advance candidates. Biocytogen expects upfront, milestones, and low single-digit royalties.

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001422142 0001422142 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

This article identifies promising "penny stocks" for May 2026, focusing on companies with strong financials and growth potential in a flat market. It highlights three specific companies: Whitehawk Therapeutics (WHWK), Caribou Biosciences (CRBU), and Zion Oil & Gas (ZNOG), detailing their current financial status, operations, and recent developments. The article emphasizes that while these companies are pre-revenue or currently unprofitable, they show potential due to factors like significant investor interest, advancing clinical trials, or strong balance sheets despite other challenges.